HHS is backing two new pathogen reduction technologies to reduce the risk of the transmission of diseases like Zika via blood product transfusions. The Cerus Corporation of Concord, Calif., will ...
CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (CERS) announced today that it has entered into a group purchasing agreement with Blood Centers of America (BCA), the largest blood supply ...
CERS develops the Intercept Blood System for platelets, plasma, and IFC. These are valuable offerings for blood transfusions. CERS Intercept provides a pathogen-reduced transfusion product suite that ...
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today two in-country regulatory approvals for INT200, one by the French National Agency for Medicines and Health Product ...
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced the start of the INITIATE study by the German Red Cross Blood Donation Service Baden-Württemberg – Hessen and its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results